Cargando…
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study
BACKGROUND: Adherence to disease-modifying therapies (DMTs) results in the reduction of the number and severity of relapses and delays the progression of multiple sclerosis (MS). Patients with lower adherence rates experience more inpatient visits and higher MS-related medical costs. Fingolimod, the...
Autores principales: | Agashivala, Neetu, Wu, Ning, Abouzaid, Safiya, Wu, You, Kim, Edward, Boulanger, Luke, Brandes, David W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851325/ https://www.ncbi.nlm.nih.gov/pubmed/24093542 http://dx.doi.org/10.1186/1471-2377-13-138 |
Ejemplares similares
-
A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod
por: Hanson, Kristin A, et al.
Publicado: (2013) -
Treatment selection and experience in multiple sclerosis: survey of neurologists
por: Hanson, Kristin A, et al.
Publicado: (2014) -
Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
por: Bergvall, Niklas, et al.
Publicado: (2014) -
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
por: Calkwood, Jonathan, et al.
Publicado: (2014) -
Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)